Growth hormone secretagogue peptides: Frequently asked questions

Switch from GHRP-6 or GHRP-2 to Ipamorelin or Hexarelin. Both produce equivalent GH pulses without activating peripheral ghrelin receptors responsible for hunger signaling. GHRP-6's ghrelin mimicry drives gastric motility and appetite through hypothalamic AgRP/NPY neuron activation, mechanisms absent in Ipamorelin's selective GHS-R1a binding profile. If caloric intake must remain stable across treatment groups, compounds with ghrelin pathway selectivity introduce an uncontrolled variable that skews energy balance data.

Choose peptide secretagogues (Ipamorelin, GHRP-2, or combination protocols) over MK-677. Physiological GH pulsatility preserves receptor sensitivity and downstream signaling efficiency. MK-677's 24-hour GH elevation produces higher total IGF-1 but blunts endogenous GH pulses and may reduce GH receptor phosphorylation in skeletal muscle and adipose tissue over time. Research examining tissue-level GH signaling rather than serum biomarkers benefits from preserving natural pulse architecture.

Either switch to Ipamorelin or GHRP-2 after 10–14 days, or dose Hexarelin intermittently (e.g., 3 days on, 4 days off) to prevent receptor downregulation. Hexarelin's high GHS-R1a affinity creates receptor occupancy levels that trigger compensatory downregulation. Continued daily dosing reduces GH pulse amplitude progressively until the response is indistinguishable from baseline. Ipamorelin maintains stable responsiveness across 4–6 weeks of daily dosing without meaningful desensitization, making it the superior choice for extended research timelines.

Use Ipamorelin exclusively or consider MK-677 for chronic models. Both produce minimal HPA axis activation. A research protocol measuring lean mass accretion or bone mineral density under GH stimulation will see attenuated treatment effects if cortisol's catabolic signaling opposes GH's anabolic pathways. The difference isn't hypothetical. Published head-to-head comparisons show 15–20% lower net anabolism in GHRP-6 groups versus Ipamorelin groups despite identical GH levels, entirely attributable to cortisol-mediated protein breakdown.

Switch to Ipamorelin or implement intermittent dosing (2–3 times weekly instead of daily). The GH response decline is receptor desensitization specific to Hexarelin and high-potency GHRPs—Ipamorelin does not produce this pattern even at 24 weeks because its receptor occupancy is shorter and selectivity for GHS-R1a reduces compensatory downregulation. If maximum GH amplitude is required, cycle Hexarelin for 4 weeks on, 4 weeks off, using Ipamorelin during off-cycle periods to maintain baseline GH support without further receptor fatigue.

Switch to MK-677 at 20–25mg oral daily. Published long-term studies (Nass et al., 2008) demonstrated sustained IGF-1 elevation and anabolic effects over two years without receptor desensitization or compliance issues. The tradeoff is loss of pulsatile GH dynamics—MK-677 produces continuous elevation rather than discrete pulses, which may not suit protocols examining ultradian rhythm effects on metabolism or gene expression.

Use Ipamorelin exclusively—it is the only GHRP with >90% selectivity for GHS-R1a and negligible affinity for receptors that stimulate ACTH (cortisol) or lactotroph (prolactin) secretion. GHRP-6, GHRP-2, and Hexarelin all produce dose-dependent cortisol elevation at research doses above 100–200 mcg/kg, which confounds metabolic endpoints (cortisol promotes gluconeogenesis and inhibits protein synthesis—opposing GH's anabolic effects). If GHRH analogs are part of the protocol, Sermorelin and CJC-1295 work through the cAMP pathway without activating stress hormone pathways, making them compatible with Ipamorelin in dual-pathway designs where endocrine selectivity is critical.

Incorporate a 10–14 day washout period and consider rotating to ipamorelin or a GHRH/ghrelin combination stack. Hexarelin's high potency comes with rapid receptor downregulation—GH output can drop by half after two months of daily dosing. Ipamorelin shows significantly less desensitization in head-to-head studies, making it better suited for chronic protocols. Alternatively, pulsing hexarelin (4 weeks on, 2 weeks off) preserves sensitivity while maintaining robust GH stimulation during active phases.

GHRH analogs (Sermorelin, CJC-1295 No DAC, Tesamorelin) degrade faster post-reconstitution than GHRPs—14–21 days at 2–8°C for GHRH analogs versus 28 days for Ipamorelin and GHRP-2. For protocols lasting >6 weeks, reconstitute only the volume needed for 2-week dosing intervals and store remaining lyophilized powder at −20°C. Alternatively, CJC-1295 with DAC eliminates this constraint through once-weekly dosing, but only if sustained basal GH elevation (rather than pulsatile release) aligns with study objectives. All lyophilized peptides from Real Peptides are stable at room temperature for 12–24 months when stored desiccated and protected from light—temperature excursions during shipping do not affect unreconstituted powder unless exposed to >40°C for extended periods.

CJC-1295 with DAC or daily MK-677 produce similar sustained GH elevation at significantly lower cost. While tesamorelin holds the only FDA approval and the most published visceral fat data, mechanistically it's a GHRH analog with pharmacokinetics similar to other compounds in that class. A 12-week protocol using 2mg weekly CJC-1295 with DAC or 25mg daily MK-677 should produce comparable lipolytic effects on visceral adipose tissue, though without the regulatory classification or clinical trial backing.

Use ipamorelin or CJC-1295—both produce negligible appetite stimulation compared to GHRP-6 or MK-677. GHRP-6 activates peripheral ghrelin receptors involved in hunger signaling, increasing food intake by 20–35% in rodent models. Ipamorelin was specifically developed for GH selectivity without appetite or cortisol effects, making it the cleanest choice for metabolic studies where caloric intake must remain controlled.

MK-677 is the only orally bioavailable growth hormone secretagogue with demonstrated efficacy—60% oral bioavailability and 24-hour GH elevation from a single daily dose. The trade-off is appetite stimulation, which increases food intake by 20–30% in rodent models with ad libitum access. Control this variable through time-restricted feeding protocols (administering food at fixed intervals post-dose) or pair-feeding controls where MK-677-treated and vehicle-treated groups receive identical caloric intake. Subcutaneous peptides like Ipamorelin and Sermorelin are not orally bioavailable—gastric proteases cleave the peptide backbone within minutes of ingestion, yielding inactive fragments.